Literature DB >> 26587312

CD4+ T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs.

Danila Valmori1, Maha Ayyoub2.   

Abstract

In a recent study, we have demonstrated that T helper type 1 (TH1) cells specific for the tumor antigen NY-ESO-1 are amplified at ovarian tumor sites but are not "perverted" into immunosuppressive FOXP3+ regulatory T cells (Tregs). These findings encourage the development of protocols aiming to eliminate, or inactivate, FOXP3+ Tregs and reinforce Type I anticancer immunity, to improve clinical outcomes.

Entities:  

Keywords:  CD4+ T cells; MHC class II tetramers; NY-ESO-1; Treg; ovarian cancer

Year:  2014        PMID： 26587312      PMCID： PMC4635782          DOI： 10.4161/21624011.2014.946370

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

3.  Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Authors:  Maha Ayyoub; Danijel Dojcinovic; Pascale Pignon; Isabelle Raimbaud; Julien Schmidt; Immanuel Luescher; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.

Authors:  Maha Ayyoub; Pascale Pignon; Jean-Marc Classe; Kunle Odunsi; Danila Valmori
Journal:  Cancer Immunol Res       Date:  2013-08-19       Impact factor: 11.151

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Authors:  Danila Valmori; Naira E Souleimanian; Valeria Tosello; Nina Bhardwaj; Sylvia Adams; David O'Neill; Anna Pavlick; Juliet B Escalon; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Gregory Mears; Susan M Vogel; Linda Pan; Achim A Jungbluth; Eric W Hoffmann; Ralph Venhaus; Gerd Ritter; Lloyd J Old; Maha Ayyoub
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

8.  CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

Authors:  Nassima Redjimi; Caroline Raffin; Isabelle Raimbaud; Pascale Pignon; Junko Matsuzaki; Kunle Odunsi; Danila Valmori; Maha Ayyoub
Journal:  Cancer Res       Date:  2012-07-12       Impact factor: 12.701

9.  NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Authors:  Nassima Redjimi; Karine Duperrier-Amouriaux; Isabelle Raimbaud; Immanuel Luescher; Danijel Dojcinovic; Jean-Marc Classe; Dominique Berton-Rigaud; Jean-Sébastien Frenel; Emmanuelle Bourbouloux; Danila Valmori; Maha Ayyoub
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

10.  The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

Authors:  Claudia C Preston; Matthew J Maurer; Ann L Oberg; Daniel W Visscher; Kimberly R Kalli; Lynn C Hartmann; Ellen L Goode; Keith L Knutson
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.